LACHENAIE, QC, Dec. 20, 2013 /CNW Telbec/ - Capital Pro-Égaux Inc. (the
"Company") (NEX: CPE.H) announces that its wholly owned subsidiary,
Technique d'usinage Sinlab Inc. ("Sinlab"), has filed an action for
damages it believes are the result of professional malpractice of
certain former legal counsels of Sinlab in connection with matters
pertaining to the recently announced settlements involving Delcam USA,
Inc. and Delcam Holdings, Inc., Cagenix, Inc., Dentsply International
Inc. and the Nobel Entities, comprised of Nobel Biocare AB; Nobel
Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare
Deutschland GmbH; Nobel Biocare Canada, Inc.; Biocad Médical Inc.;
Nobel Biocare USA, LLC; and Nobel Biocare Procera, LLC.
Caution regarding forward-looking statements
This news release contains certain forward-looking statements regarding
the Company's expectation of future events, including potential claims
and legal proceedings. Such expectations are based on certain
assumptions based on currently available information. If these
assumptions prove incorrect, actual results may differ materially from
those contemplated by the forward-looking statements contained in this
press release. Factors that could lead actual results to differ
include, amongst others, factors that may impact claims and legal
proceedings, such as interpretation of factual matters, time and money
involved in undertaking legal proceedings, uncertainty as to the final
result and other risks. The Company disclaims any intention or
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
other than as required by securities laws.
About Pro-Égaux Inc.
Pro-Égaux through its wholly owned subsidiary, Technique d'usinage
Sinlab Inc., is a company based in Lachenaie, Quebec, specializing
mainly in the conception and design of titanium products to be used in
the dental prosthesis restoration industry.
Neither NEX, the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of NEX and the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
SOURCE: Capital Pro-Égaux Inc.
For further information:
Capital Pro-Égaux Inc.
Fax: (450) 226-1923